All News
EULAR 2022 Featured Industry Abstracts
Below is a collection of several EULAR 2022 abstracts highlighted in recent press releases from companies sponsoring major clinical trials. You can search the EULAR site for these abstract and others here.
Read Article
Another promising drug for #SLE! Monoclonal Ab to BDCA2 ; phase II study noted improvement in joint manifestation but not impressive in cutaneous dz. - Prof T Dorner #EULAR2022 @rheumnow https://t.co/eKwQyomJUD
TheDaoIndex KDAO2011 ( View Tweet)
#ClinicalPearl 2/3 of pts with #SLE have Type 1 interferon signature. So, 1/3 of #lupus is NOT driven by this pathway. Importance may be what is targeted in each pt but doesn’t necessarily predict response to #anifrolimumab #EULAR2022 @eular_org @RheumNow T Dorner SLE session https://t.co/vMOC8yGJ2V
Janet Pope Janetbirdope ( View Tweet)
#OP0144 #EULAR2022 Promising Digital use in monitoring disease activity for clinicians. Researchers in Amsterdam developed the first e-health #SLE T2T. High acceptance rate re: usability. Need more validation and in different languages @RheumNow https://t.co/7LravXhoJ8
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ClinicalPearl #SLE has ⬆️mortality until v advanced age and if not in remission or v low disease activity Mortality is higher. Ideas: control disease activity, prevent damage, limit prednisone. @RheumNow #EULAR2022 T Dormer Session #Lupus https://t.co/90cpsBVgAb
Janet Pope Janetbirdope ( View Tweet)
#OP0141 #EULAR2022 What do our #lupus patients think about Treat-to-target (T2T) and are they involved? A patient survey showed improvement in QoL as most important. They were open to T2T concept but concerned of more visits + new drugs. 61% felt they were involved @RheumNow https://t.co/rT500lhrih
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#POS0114 #EULAR2022 Can we identify #lupus patients better in electronic health records? Barbero et al. used machine learning and developed a model to distinguish SLE diagnosis vs "near-misses". AUC: 0.90. Further validation can help future epidemiological studies @RheumNow https://t.co/vpLH8SWlWm
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Severe heme relapses are common in #SLE pts w/prior severe heme episodes: ATTIKON SLE cohort 800 pts
👉13% w/severe heme dz: TMA, MAS, plt < 30K, hemolysis hgb < 8
👉heme issues preceded SLE dx in 1/3 of pts
👉>50% pts had severe heme flare
👉0 deaths #EULAR2022 @rheumnow POS0116
TheDaoIndex KDAO2011 ( View Tweet)
Low rates of hypersensitivity reactions (HSR) to #anifrolumab
Pooled data MUSE & TULIP-1/-2 w/1100 pts:
👉1 anaphylaxis (0.15%)
👉12 HSR (3%)
👉43 infusion reaction (9%): N/V/headache
👉most easily treatable w/antihistamine, GCs, acetaminophen
#EULAR2022 POS0708 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
#POS0086PARE #EULAR2022 What #lupus symptoms/target mattered most to the patients?A survey in 342 found reduction in joint pain, rash & non-joint pain as most important. Reduced infection risk was the least. Important to be aware in assessing patients & guide studies @RheumNow https://t.co/pGXxklj1mt
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#OP0002 #EULAR2022 What immune tests to monitor during pregnancy in #lupus? A meta-analysis found:
💠32% had a flare (new IS or Pred>9mg/d)
💠⬇️C3 and/or C4 in 1st Trimester predicted LN or SLE flare
Worth checking C3/C4 in each trimester @RheumNow https://t.co/fPEXwReK7u https://t.co/BX6fzKzfvC
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#POS0183 #EULAR2022 Pooled analyses of 5 Belimumab RCTs showed better response vs PBO in those:
💠SLEDAI=>10
💠dsDNA+ve + ⬇️C3 and/ ⬇️C4
💠⬇️C3 and/ C4 pre-treatment
💠Response high regardless SDI, Steroid, #lupus duration
@RheumNow https://t.co/fLggazbRQu
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#POS0190 #EULAR2022 Disappointing news. Despite +ve Phase 2 RCT, Results from Phase 3 RCTs of Baricitinib in #lupus is inconclusive
💠SRI4 was met in BRAVE1 but not BRAVE2 despite identical study
💠BILAG MSK & Skin improved in BRAVE1 only
BICLA wasn’t reported @RheumNow https://t.co/IfJRYEwFY8
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#POS0186 #EULAR2022 AURORA2 (Extension of original RCT to 2 years) showed:
💠#lupus nephritis patients on voclosporin maintained meaningful low uPCR and stability of eGFR at 2yrs
💠No unexpected safety signals
@RheumNow https://t.co/lnohgW7BsK
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Sustained benefits #voclosporin in #LupusNephritis AURORA2 - 2 year study POS0186:
👉no unexpected AEs; rate of AEs⬇️over time
👉COVID19 seen in 12 controls, 7 VCS
👉4 deaths w/control arm vs 0 deaths w/ VCS
👉GFR & sCr & reduction in UPCR remained stable #EULAR2022 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
Can SGLT2 Inhibitors Be Protective in Lupus and Vasculitis?
SGLT2 inhibitors are all the buzz in the renal world with reports of a renal protective and mortality lowering effects
https://t.co/b7YupKPJr7
#MedEd https://t.co/AYPeX360Gv
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch: Lupus Nephritis: The Blind Men and the Kidney with Dr. Joan Merrill
Joan Merrill discusses treatment of lupus nephritis. This was previously recorded at RheumNow Live 2022.
https://t.co/9GRw5VGTKr https://t.co/PS6aEk1fsx
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Jack Cush reviews the news, regulatory updates and journal reports from the past week on https://t.co/V10S4oVFsv. This week gout worries, mortality risks, measuring anti-drug antibodies and a better way in lupus?
https://t.co/iaMQZtzdLm https://t.co/Zu9VwKoCAc
Dr. John Cush RheumNow ( View Tweet)
Looking forward to reading/watching the coverage of #EULAR2022 by our outstanding faculty, including Drs., Rachel Tate @uptoTate, Kathryn Dao @KDAO2011,
Robert Chao @doctorRBC , Janet Pope @Janetbirdope and Antoni Chan @synovialjoints . https://t.co/oBQCxzdzfF
Dr. John Cush RheumNow ( View Tweet)
Watch: Novel Treatment of SLE
Dr. Sonali Narain discusses new insights on existing treatments and newly approved therapy and soon to be approved therapies for SLE. #MedEd
https://t.co/7Op3R8IzV1
#MedEdTwitter https://t.co/qBMTbOBmyM
Links:
Dr. John Cush RheumNow ( View Tweet)
